Navigation Links
Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques in Living Brain
Date:2/18/2009

NEW YORK, Feb. 18 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research awarded approximately $1.9 million total to six teams working to develop neuroimaging technologies that would allow scientists to non-invasively visualize the clumping of the alpha-synuclein protein in the living human brain. Such technologies would dramatically accelerate research into the cause, progression and treatment of PD. Investigators could more accurately identify individuals with PD as well as better characterize disease pathology and relate it to clinical measures of onset and progression. There is also growing interest in therapeutics that directly target alpha-synuclein; hence, a non-invasive imaging tool would be a useful therapeutic response marker for drug makers wishing to test biological impact of potentially disease-modifying drugs. Such tools would have a huge impact on clinical trial designs, allowing for more accurate patient selection and clearer trial outcome measures.

This program was funded with a lead gift from The Edmond J. Safra Foundation in memory of its founder, Mr. Edmond J. Safra. The Edmond J. Safra Foundation has been one of the most steadfast supporters of The Michael J. Fox Foundation since its inception.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available on the Foundation's Searchable Database of Funded Grants.

As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Development and Screening of Contrast Agents for In Vivo Imaging of PD

Brian Bacskai, PhD, and Pamela McLean, PhD, Massachusetts General Hospital (Harvard Medical School), Boston, Massachusetts

Utility of the Amyloid Ligand [18F] FDDNP in Human PET Imaging in Parkinson's Disease

Yvette Bordelon, MD, PhD, University of California, Los Angeles

18F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies

Franz Hefti, PhD, Avid Radiopharmaceuticals, Inc., Philadelphia, Pennsylvania, and Alan Snow, PhD, ProteoTech, Inc., Seattle, Washington

Generation of Alpha-Synuclein Conformation-specific Aptamers for In Vivo Bioimaging of Alpha-Synuclein Pathology

Poul Henning Jensen, MD, PhD, University of Aarhus, Aarhus, Denmark

A Strategy to Develop a Radiotracer Targeting Alpha-Synuclein

Kenneth Marek, MD, Institute for Neurodegenerative Disorders, New Haven, Connecticut, and Omar El-Agnaf, PhD, United Arab Emirates University

In Vivo SPECT Imaging of Synuclein Aggregation with Morphology-specific Antibody-based Ligands

Michael Sierks, PhD, Arizona State University, Tempe, Arizona

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded about $140 million in research to date.

About Edmond J. Safra

Considered by many to have been among the greatest bankers of his generation, Edmond J. Safra was also an extraordinary philanthropist. He contributed to countless humanitarian, religious, educational and cultural causes the world over. He was deeply committed to the search for a cure for neurodegenerative diseases, in particular Parkinson's disease, and made the support of medical research in this field one of the key objectives when he established The Edmond J. Safra Foundation. He shared his devotion to this cause with his wife, Mrs. Lily Safra, a member of the Board of The Michael J. Fox Foundation for Parkinson's Research and, since her husband's passing in 1999, Chairman of The Edmond J. Safra Foundation.


'/>"/>
SOURCE The Michael J. Fox Foundation for Parkinson's Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Former Health & Human Services Secretary Michael Leavitt To Address Health Plan Member Retention Summit
2. Former Health & Human Services Secretary Michael Leavitt to Address Health Plan Member Retention Summit
3. Michael J. Fox Foundation Awards $2.5 Million for Parkinsons Drug Development Projects Led By Academic Investigators
4. Suzanne Somers Appears on CNBCs Conversations with Michael Eisner and Discusses NeoStems Adult Stem Cell Collection Program
5. KineMatik Group Ltd. Appoints Michael G. Jarjour as President & CEO
6. Michael Kincaid Named Executive Vice President, Chief Financial Officer and Treasurer of HVHC Inc.
7. NYC Mayor Michael R. Bloomberg Declares January 8th IBREA Brain Education Day
8. Davis Vision, Inc. Names Michael Ehrle Divisional Vice President of Sales
9. DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations
10. Posit Science Co-Founder and Brain Plasticity Pioneer, Michael Merzenich, Speaks at Science Conference in the Netherlands
11. ESPN'S Dick Vitale and Michael Wilbon Stand Up in the Fight Against Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For ... assistance management solution to the exhibit floor for the 2017 HIMSS Conference ... , From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected ...
(Date:2/17/2017)... Seattle, WA (PRWEB) , ... February 17, 2017 ... ... health management organizations, has been named a finalist in the 8th Annual DecisionHealth ... impacting America's healthcare delivery system. Qualis Health’s work is recognized across multiple award ...
(Date:2/17/2017)... ... 2017 , ... Pharmica Consulting attended CHI's 8th Annual SCOPE ... trial planning and management. Pharmica discussed the importance of effective project management, data ... by Pharmica’s booth were able to demo its cloud-based Resource Management Tool, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists from ... February 21 - 23 in Beaver Creek, CO. It was announced today by Cindy ... year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs of ...
(Date:2/16/2017)... ... 17, 2017 , ... For some cancer survivors, the memories ... Physician researchers at The Marcus Institute of Integrative Health at Thomas Jefferson ... reducing symptoms of traumatic stress in cancer patients and published their results ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... 17, 2017  Noble Capital Markets announced today that ... (Nasdaq: EPIX ). The report was issued ... , PhD. ESSA Pharmaceuticals is a clinical ... cancer (CRPC). Its lead compound EPI-506, is a small ... of the androgen receptor, thereby has potential to overcome ...
(Date:2/16/2017)... Quest Diagnostics (NYSE: DGX ), ... announced that it has been named one of the ... The annual survey designated Quest Diagnostics as ... Pharmacy and Other Services" industry to attain Most Admired ... attain the designation. This is the second consecutive year ...
(Date:2/16/2017)... Feb. 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... company, today announced that executive management will participate in ... held February 22-23, 2017. Adrian Adams , Chief ... at 1:35 p.m. local time on Wednesday, February 22, ... for the event may be accessed from the Investors ...
Breaking Medicine Technology: